Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma
BioMed Research International · 2023
DOI: 10.1155/2023/7214037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioMed Research International, 2023. Verfasst von Nian Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Ginsenosides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Ginsenosides, the main active pharmacological ingredients of ginseng, have been widely used for the treatment of numerous carcinomas. Hepatocellular carcinoma (HCC) is 3 rd leading malignant tumor in terms of mortality worldwide. Accumulating evidence indicates that ginsenosides play a vital role in the prevention and treatment of HCC. Ginsenosides can significantly improve the symptoms of HCC, and their anticancer activity is mainly involved in inhibiting proliferation and migration, inducing cell cycle arrest at the G0/G1 phase, promoting caspase‐3 and 8‐mediated apoptosis, regulating autophagy related to Atg5, Atg7, Atg12, LC3‐II, and PI3K/Akt pathways, and lowering invasion and metastasis associated with decreased nuclear translocation of NF‐ κ B p65 and MMP‐2/9, increasing IL‐2 and IFN‐ γ levels to enhance immune function, as well as regulating the gut‐liver axis. In addition, ginsenosides can be used as an adjuvant to conventional cancer therapies, enhancing sensitivity to chemotherapy drugs, and improving efficacy and/or reducing adverse reactions through synergistic effects. Therefore, the current manuscript discusses the mechanism and application of ginsenosides in HCC. It is hoped to provide theoretical basis for the treatment of HCC with ginsenosides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
- Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200438, China.
ORCID-Profile: Nian Zhou, Shuqun Cheng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, N., Mao, F., & Cheng, S. (2023). Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma. BioMed Research International. https://doi.org/10.1155/2023/7214037
Vancouver
Zhou N, Mao F, Cheng S. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma. BioMed Research International. 2023. doi:10.1155/2023/7214037
BibTeX
@article{Zhou2023,
author = {Zhou, Nian and Mao, Feifei and Cheng, Shuqun},
title = {Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma},
journal = {BioMed Research International},
year = {2023},
doi = {10.1155/2023/7214037}
}
EUVIMED